Companies
Akoya Biosciences
Akoya's PhenoCycler-Fusion is the spatial-proteomics leader, detecting 100-plus protein biomarkers per section at 0.25 µm/pixel with cyclic immunofluorescence plus in-situ-hybridisation RNA modules;…
- Country
- United States
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Raised about $262.1 million total in gross disclosed equity financing, including private rounds, its 2021 IPO, and a 2023 follow-on offering (2023-06-12) | biobase.whitefordresearch.com |
| Capacity | 5–100 tissue sections per week for the PhenoCycler-Fusion platform (2026-03-06) | instrumenthive.com |
| Certification | ABS laboratory in Marlborough, Massachusetts is CLIA certified (2024-12-31) | sec.gov |
| Regulatory approval | PhenoCycler-Fusion complies with FDA 21 CFR Part 11 requirements for electronic records and signatures when used with validated software (2026-03-06) | instrumenthive.com |
| Production site | Manufacturing facility in Marlborough, Massachusetts (2024-12-31) | investors.akoyabio.com · sec.gov |
| Headcount | 205 employees (2024-12-31) | sec.gov |
| Revenue | $81.7 million total revenue for the year 2024 (2024-12-31) | sec.gov |
Independent sources: biobase.whitefordresearch.com · instrumenthive.com · investors.akoyabio.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Spatial transcriptomics & spatial multi-omics | bioinformatics-omics | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.